Breast Cancer Drug Data Boosts Puma Biotechnology
Puma Biotechnology (PBYI) stock vaulted 42% to a new high in morning trading on the stock market today after the company reported surprisingly strong data from a phase-two trial of its breast cancer drug. The study gave a regimen of Puma’s neratinib combined with paclitaxel (better known as Bristol-Myers Squibb’s (BMY) Taxol) to 115 patients with breast cancer at Stage 2 or worse, and compared those patients with a control group given paclitaxel